Serum APPs were found to be of value in supporting the diagnosis of SRMA and monitoring its treatment. C-reactive protein (CRP), serum amyloid-A (SAA), alpha-1-acid glycoprotein (AGP) and haptoglobin (Hp) all exhibited an increase above our laboratory reference range in nine patients at initial presentation. During treatment APPs decreased significantly compared to presentation except Hp which increased (Wilcoxon–Signed–Rank-test: CRP, SAA and AGP P < ). Serum CRP and SAA were also found to be of clinical value in the identification of putative relapse (seven cases), particularly in the light of unperturbed CSF parameters where APP concentrations were elevated. CSF APPs were found to be less reliable markers in the management of this disease. The results indicate that SRMA causes a significant APP response in dogs, which although not disease specific, is of value in supporting the diagnosis of SRMA.
There is no known cure for polymyalgia rheumatica and giant cell arteritis, but these conditions can be treated and controlled. Corticosteroids - often called ‘steroids’ - help to rapidly relieve the symptoms of both polymyalgia rheumatica and giant cell arteritis.
Treatment with steroids - usually in the form of prednisolone - is mandatory for giant cell arteritis to prevent serious complications such as blindness. Low doses of steroids are often successful in treating polymyalgia rheumatica. Higher doses are often required to treat giant cell arteritis.
The excellent response to treatment is so uniform that a lack of dramatic improvement within days would make the diagnosis of giant cell arteritis or polymyalgia rheumatica doubtful.
The first-line treatment for arteritis is oral glucocorticoid (steroid) medication, such as prednisone, taken daily for a period of three months.  After this initial phase, the medication may be reduced in dose or frequency, . every other day, if possible.  If the disease worsens with the new treatment schedule, a cytotoxic medication may be given, in addition to the glucocorticoid.  Commonly used cytotoxic agents include azathioprine, methotrexate, or cyclophosphamide.  The dose of glucocorticoid medication may be decreased if response to treatment is good.  This medication may be reduced gradually once the disease becomes inactive, slowly tapering the dose (to allow the body time to adjust) until the medication may be stopped completely.  Conversely, if the disease remains active, the medication will need to be increased.  After six months, if the medication cannot be reduced in frequency to alternate days, or if in 12 months the medications cannot be stopped completely, then treatment is deemed to have failed.